Targeting upstream effectors of ERK with pharmacologic inhibitors yielded promising results [8] and clinical trials with combined PI3K and BRAF inhibitors, reported to inhibit melanoma tumor growth in mice [9], are currently in progress [10]. This evidence concerns the gene BRAF and melanoma.